NASDAQ:NKNantkwest Stock Price, Forecast & News

$7.49

-0.01 (-0.13 %)

(As of 06/3/2020 08:52 AM ET)

Add

Compare

Today's Range

$7.13

Now: $7.49▼

$7.76

50-Day Range

$2.99

MA: $4.46▼

$7.58

52-Week Range

$0.95

Now: $7.49▼

$9.90

Volume998,306 shs

Average Volume2.31 million shs

Market Capitalization$737.84 million

P/E RatioN/A

Dividend YieldN/A

Beta3.06

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Nantkwest.

2.6 Community Rank

Outperform Votes
Nantkwest has received 265 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Nantkwest has received 251 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Nantkwest has received 51.36% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote “Outperform” if you believe NK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Nantkwest does not currently pay a dividend.
Dividend Growth
Nantkwest does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nantkwest insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $925,239.00 in company stock.
Percentage Held by Insiders
72.08% of the stock of Nantkwest is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 6.19% of the stock of Nantkwest is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Nantkwest are expected to decrease in the coming year, from ($0.52) to ($0.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nantkwest is -11.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nantkwest is -11.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nantkwest has a P/B Ratio of 6.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.72 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:NK

Previous Symbol

CUSIPN/A

CIK1326110

Webwww.nantkwest.com

Phone858-633-0300

Debt

Debt-to-Equity Ratio0.10

Current Ratio3.10

Quick Ratio3.10

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00

Price / Sales18,446.00

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.23 per share

Price / Book6.09

Profitability

EPS (Most Recent Fiscal Year)($0.70)

Net Income$-65,790,000.00

Net Margins-112,350.85%

Return on Equity-51.94%

Return on Assets-43.75%

Miscellaneous

Employees161

Outstanding Shares98,510,000

Market Cap$737.84 million

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive NK News and Ratings via Email

Sign-up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.

Nantkwest (NASDAQ:NK) Frequently Asked Questions

How has Nantkwest's stock been impacted by COVID-19 (Coronavirus)?

Nantkwest's stock was trading at $3.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NK stock has increased by 112.8% and is now trading at $7.49. View which stocks have been most impacted by Coronavirus.

When is Nantkwest's next earnings date?

Nantkwest is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Nantkwest.

How were Nantkwest's earnings last quarter?

Nantkwest Inc (NASDAQ:NK) issued its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. Nantkwest had a negative net margin of 112,350.85% and a negative return on equity of 51.94%. View Nantkwest's earnings history.

Has Nantkwest been receiving favorable news coverage?

Media stories about NK stock have been trending positive on Wednesday, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nantkwest earned a news sentiment score of 2.4 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutNantkwest.

Are investors shorting Nantkwest?

Nantkwest saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,910,000 shares, an increase of 35.3% from the April 30th total of 3,630,000 shares. Based on an average daily trading volume, of 922,300 shares, the short-interest ratio is presently 5.3 days. Currently, 17.7% of the company's stock are short sold. View Nantkwest's Current Options Chain.

Who are some of Nantkwest's key competitors?

Some companies that are related to Nantkwest include Novavax (NVAX), Alector (ALEC), Fate Therapeutics (FATE), Bill.com (RVMD), Adverum Biotechnologies (ADVM), SpringWorks Therapeutics (SWTX), Sangamo Therapeutics (SGMO), Twist Bioscience (TWST), Mesoblast (MESO), Editas Medicine (EDIT), Adaptimmune Therapeutics (ADAP), I-Mab (BDTX), Beam Therapeutics (BEAM), Regenxbio (RGNX) and Coherus Biosciences (CHRS). View all competitors.

What other stocks do shareholders of Nantkwest own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nantkwest investors own include Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Novavax (NVAX), Mallinckrodt (MNK), Opko Health (OPK), Amicus Therapeutics (FOLD), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Bausch Health Companies (BHC) and Fate Therapeutics (FATE).

Who are Nantkwest's key executives?

Nantkwest's management team includes the following people:

Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 66)
Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 54)
Mr. Richard J. Tajak, Consultant (Age 66)
Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 46)
Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 62)

When did Nantkwest IPO?

(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.

What is Nantkwest's stock symbol?

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

Who are Nantkwest's major shareholders?

Nantkwest's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.69%), Geode Capital Management LLC (0.33%), Morgan Stanley (0.07%), Horizon Kinetics Asset Management LLC (0.05%), Creative Planning (0.05%) and Two Sigma Investments LP (0.04%). Company insiders that own Nantkwest stock include Barry J Simon, John C Thomas and Steve Gorlin. View institutional ownership trends for Nantkwest.

Which institutional investors are selling Nantkwest stock?

NK stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Horizon Kinetics Asset Management LLC, First Allied Advisory Services Inc., BlackRock Inc., and State Street Corp. Company insiders that have sold Nantkwest company stock in the last year include Barry J Simon, and John C Thomas. View insider buying and selling activity for Nantkwest.

Which institutional investors are buying Nantkwest stock?

NK stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Deutsche Bank AG, Geode Capital Management LLC, Creative Planning, Invesco Ltd., Squarepoint Ops LLC, and GSA Capital Partners LLP. View insider buying and selling activity for Nantkwest.

How do I buy shares of Nantkwest?

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nantkwest's stock price today?

One share of NK stock can currently be purchased for approximately $7.49.

How big of a company is Nantkwest?

Nantkwest has a market capitalization of $737.84 million and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Nantkwest employs 161 workers across the globe.

What is Nantkwest's official website?

The official website for Nantkwest is www.nantkwest.com.

How can I contact Nantkwest?

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff